GLP1R and metabolic dysfunction-associated steatohepatitis: Considering the low GLP-1R expression in the liver, the potential action mechanism of GLP-1R agonists (GLP-1RA) in NASH might be associated with their indirect positive effects on body weight, IR, and the mitigation of metabolic dysfunction, as well as their ability to counteract lipotoxic effects and inflammation [89].